Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype

NCT01450319 is registered in ClinicalTrials.gov with Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT01450319
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01450319 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Clinical Study of Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favourable FcγR IIa (CD32) Genotype
Lead sponsor
Merck KGaA, Darmstadt, Germany
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2011
Completion date
December 31, 2014
Enrollment
73 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal neoplasms